Clinical trial · Interventional
Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer
Single Centre，Exploratory，Parallel and Retrospective Study to Analysis the Mutation and Expression of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is to determine the prevalence of potential chemo-response related genes mutation in TNBC patients between pCR and SD/PD group, which achieved after NAC; and to evaluate potential relationship between these gene mutations and NAC-response in TNBC patients.Based on the results,we can further characterize TNBC from a phenotypical and molecular perspective, in order to identify potential new target agents and to individualize the treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mutation analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Mutation analysis- NACwith PCR
- description
- consisting of 50 patients undergoing NACwith pathological compete response
- interventionNames
- Other: Mutation analysis
- type
- EXPERIMENTAL
- label
- Mutation analysis-NAC with SD/PD.
- description
- consisting of 50 patients undergoing NAC with SD/PD
- interventionNames
- Other: Mutation analysis
Primary outcomes (1)
- measure
- Gene mutation prevalence of tBRCA1/2, HRR, or other chemo-response related genes in TNBC patients between pCR and SD/PD, which achieved after NAC
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: Patients receiving neoadjuvant chemotherapy with paclitaxel and carboplation are enrolled in this study. * (1) histologically confirmed mainly invasive breast carcinoma * (2) a unilateral and non-inflammatory tumors * (3) status of ER, PR and HER-2 are available and negative * (4) The participants are required to have clinical stage II or III breast cancer with a clinical or radiographically measurable residual tumor after core biopsy. * (5)patients had pathological evaluation after NAC * (6) the pathologic tissues are available for immunohistochemistry and next generation sequencing Exclusion Criteria: * (1) carcinoma in situ * (2) received less than 4 cycles neoadjuvant chemotherapy
References
Publications (0)
Data not yet available